Selected research
Market Structure
Global Anti-Viral Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Anti-Viral Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Anti-Viral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Anti-Viral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-Viral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Anti-Viral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Anti-Viral Drugs include Aurobindo Pharma, Bristol-Myers-Squibb, Cipla, Dr Reddy’s, F. Hoffmann-La Roche, AbbVie, GlaxoSmithKline, Merck & Co and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Anti-Viral Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti-Viral Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-Viral Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Viral Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti-Viral Drugs Segment by Company
Aurobindo Pharma
Bristol-Myers-Squibb
Cipla
Dr Reddy’s
F. Hoffmann-La Roche
AbbVie
GlaxoSmithKline
Merck & Co
Johnson & Johnson
Anti-Viral Drugs Segment by Type
Reverse Transcriptase Inhibitor
Nucleotide Polymerase Inhibitor
Protease Inhibitor
Anti-Viral Drugs Segment by Application
HIV
Influenza
Hepatitis
HSV
Anti-Viral Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Viral Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Viral Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Viral Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Anti-Viral Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Viral Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-Viral Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Anti-Viral Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Reverse Transcriptase Inhibitor
- Nucleotide Polymerase Inhibitor
- Protease Inhibitor
Applications
- HIV
- Influenza
- Hepatitis
- HSV
Companies covered
- Aurobindo Pharma
- Bristol-Myers-Squibb
- Cipla
- Dr Reddy’s
- F. Hoffmann-La Roche
- AbbVie
- GlaxoSmithKline
- Merck & Co
- Johnson & Johnson
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Anti-Viral Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Anti-Viral Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Anti-Viral Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Anti-Viral Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Anti-Viral Drugs Market Dynamics
- 2.1 Anti-Viral Drugs Industry Trends
- 2.2 Anti-Viral Drugs Industry Drivers
- 2.3 Anti-Viral Drugs Industry Opportunities and Challenges
- 2.4 Anti-Viral Drugs Industry Restraints
3 Anti-Viral Drugs Market by Manufacturers
- 3.1 Global Anti-Viral Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Anti-Viral Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Anti-Viral Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Anti-Viral Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Anti-Viral Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Anti-Viral Drugs Manufacturers, Product Type & Application
- 3.7 Global Anti-Viral Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Anti-Viral Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Anti-Viral Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Anti-Viral Drugs Tier 1, Tier 2, and Tier 3
4 Anti-Viral Drugs Market by Type
- 4.1 Anti-Viral Drugs Type Introduction
- 4.1.1 Reverse Transcriptase Inhibitor
- 4.1.2 Nucleotide Polymerase Inhibitor
- 4.1.3 Protease Inhibitor
- 4.2 Global Anti-Viral Drugs Sales by Type
- 4.2.1 Global Anti-Viral Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Anti-Viral Drugs Sales by Type (2021-2032)
- 4.2.3 Global Anti-Viral Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Anti-Viral Drugs Revenue by Type
- 4.3.1 Global Anti-Viral Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Anti-Viral Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Anti-Viral Drugs Revenue Market Share by Type (2021-2032)
5 Anti-Viral Drugs Market by Application
- 5.1 Anti-Viral Drugs Application Introduction
- 5.1.1 HIV
- 5.1.2 Influenza
- 5.1.3 Hepatitis
- 5.1.4 HSV
- 5.2 Global Anti-Viral Drugs Sales by Application
- 5.2.1 Global Anti-Viral Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Anti-Viral Drugs Sales by Application (2021-2032)
- 5.2.3 Global Anti-Viral Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Anti-Viral Drugs Revenue by Application
- 5.3.1 Global Anti-Viral Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Anti-Viral Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Anti-Viral Drugs Revenue Market Share by Application (2021-2032)
6 Global Anti-Viral Drugs Sales by Region
- 6.1 Global Anti-Viral Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Anti-Viral Drugs Sales by Region (2021-2032)
- 6.2.1 Global Anti-Viral Drugs Sales by Region (2021-2026)
- 6.2.2 Global Anti-Viral Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Anti-Viral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Anti-Viral Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Anti-Viral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Anti-Viral Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Anti-Viral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Anti-Viral Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Anti-Viral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Anti-Viral Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Anti-Viral Drugs Revenue by Region
- 7.1 Global Anti-Viral Drugs Revenue by Region
- 7.1.1 Global Anti-Viral Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Anti-Viral Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Anti-Viral Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Anti-Viral Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Anti-Viral Drugs Revenue (2021-2032)
- 7.2.2 North America Anti-Viral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Anti-Viral Drugs Revenue (2021-2032)
- 7.3.2 Europe Anti-Viral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Anti-Viral Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Anti-Viral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Anti-Viral Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Anti-Viral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Aurobindo Pharma
- 8.1.1 Aurobindo Pharma Company Information
- 8.1.2 Aurobindo Pharma Business Overview
- 8.1.3 Aurobindo Pharma Anti-Viral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Aurobindo Pharma Anti-Viral Drugs Product Portfolio
- 8.1.5 Aurobindo Pharma Recent Developments
- 8.2 Bristol-Myers-Squibb
- 8.2.1 Bristol-Myers-Squibb Company Information
- 8.2.2 Bristol-Myers-Squibb Business Overview
- 8.2.3 Bristol-Myers-Squibb Anti-Viral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Bristol-Myers-Squibb Anti-Viral Drugs Product Portfolio
- 8.2.5 Bristol-Myers-Squibb Recent Developments
- 8.3 Cipla
- 8.3.1 Cipla Company Information
- 8.3.2 Cipla Business Overview
- 8.3.3 Cipla Anti-Viral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Cipla Anti-Viral Drugs Product Portfolio
- 8.3.5 Cipla Recent Developments
- 8.4 Dr Reddy’s
- 8.4.1 Dr Reddy’s Company Information
- 8.4.2 Dr Reddy’s Business Overview
- 8.4.3 Dr Reddy’s Anti-Viral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Dr Reddy’s Anti-Viral Drugs Product Portfolio
- 8.4.5 Dr Reddy’s Recent Developments
- 8.5 F. Hoffmann-La Roche
- 8.5.1 F. Hoffmann-La Roche Company Information
- 8.5.2 F. Hoffmann-La Roche Business Overview
- 8.5.3 F. Hoffmann-La Roche Anti-Viral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 F. Hoffmann-La Roche Anti-Viral Drugs Product Portfolio
- 8.5.5 F. Hoffmann-La Roche Recent Developments
- 8.6 AbbVie
- 8.6.1 AbbVie Company Information
- 8.6.2 AbbVie Business Overview
- 8.6.3 AbbVie Anti-Viral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 AbbVie Anti-Viral Drugs Product Portfolio
- 8.6.5 AbbVie Recent Developments
- 8.7 GlaxoSmithKline
- 8.7.1 GlaxoSmithKline Company Information
- 8.7.2 GlaxoSmithKline Business Overview
- 8.7.3 GlaxoSmithKline Anti-Viral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 GlaxoSmithKline Anti-Viral Drugs Product Portfolio
- 8.7.5 GlaxoSmithKline Recent Developments
- 8.8 Merck & Co
- 8.8.1 Merck & Co Company Information
- 8.8.2 Merck & Co Business Overview
- 8.8.3 Merck & Co Anti-Viral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Merck & Co Anti-Viral Drugs Product Portfolio
- 8.8.5 Merck & Co Recent Developments
- 8.9 Johnson & Johnson
- 8.9.1 Johnson & Johnson Company Information
- 8.9.2 Johnson & Johnson Business Overview
- 8.9.3 Johnson & Johnson Anti-Viral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Johnson & Johnson Anti-Viral Drugs Product Portfolio
- 8.9.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Anti-Viral Drugs Value Chain Analysis
- 9.1.1 Anti-Viral Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Anti-Viral Drugs Production Mode & Process
- 9.2 Anti-Viral Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Anti-Viral Drugs Distributors
- 9.2.3 Anti-Viral Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst